Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of 1,6-Hexanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL3846619 | 0.93 | TP53 (0.61) | TP53GPR84FFAR1FFAR4CAMK2A | |
| 1,6-Hexanediol SCHEMBL3482973 | 0.93 | TP53 (0.61) | TP53GPR84FFAR1FFAR4CAMK2A | |
| Lactic Acid SCHEMBL11019396 | 0.90 | TP53 (0.65) | TP53GPR84FFAR1FFAR4CAMK2A | |
| Lactic Acid SCHEMBL8850880 | 0.90 | TP53 (0.65) | TP53GPR84FFAR1FFAR4CAMK2A | |
| Lactic Acid SCHEMBL27854300 | 0.87 | TP53 (0.61) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 | |
| Lactic Acid SCHEMBL2286708 | 0.87 | TP53 (0.69) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 | |
| Lactic Acid SCHEMBL5269783 | 0.87 | TP53 (0.69) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 | |
| Lactic Acid SCHEMBL4261279 | 0.87 | TP53 (0.69) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 | |
| Lactic Acid SCHEMBL4263083 | 0.87 | TP53 (0.69) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 | |
| Lactic Acid SCHEMBL41708 | 0.87 | TP53 (0.69) | TP53TSHRSMN1; SMN2OR51E2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | claimed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | claimed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | claimed |
| US-20180110739-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170007549-A1 | Transdermal Delivery Systems | DURECT CORPORATION | 2017-01-12 | — | — | US | disclosed |
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | DURECT CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8337883-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-7053209-B1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1212092-B1 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004052336-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-6413536-B1 | DELIVERING ACTIVE MATERIALS | SOUTHERN BIOSYSTEMS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1212092-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | Southern Biosystems, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001015734-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | SOUTHERN BIOSYSTEMS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | TP53 1769/4885GPR84 2110/4885FFAR1 4101/4885 |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | MMP1, MMP13, MMP9 | TP53 1783/4885GPR84 2124/4885FFAR1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.